Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment (BEST)

Research into biomarkers predictive of survival and response to cancer treatment

Study Overview

• Status: Recruiting
• Conditions: Cancer
• Intervention / Treatment: Other: blood sampling

• Study Type: Observational
• Enrollment (Estimated): 40000
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Victoria FERRARI, Dr; Phone Number: +33 492031311; Email: victoria.ferrari@nice.unicancer.fr

Study Locations

• France
  • Nice, France, 0600
    • Recruiting
    • Centre Antoine Lacassagne
    • Contact: Victoria FERRARI; Phone Number: +33492031311; Email: victoria.ferrari@nice.unicancer.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with cancer receiving care at Centre Antoine Lacassagne are prospectively recruited for biospecimen collection during routine clinical blood sampling.

Description

Inclusion Criteria:

• Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care,
• Patient who has read the information note and stated that he/she has no objections
• Patient who has not objected to the use of this data for medical research purposes
• Patient with social security cover.

Exclusion Criteria:

• Patient already included in the study
• Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
principal; blood sampling	Other: blood sampling; 36ml of blood will be taken during a blood sampling performed in standard practice

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prediction	The aim of this project is to make a biobank in prevision of MR004 sub-projects which define specific biomarkers studied to identify biomarkers predictive of response.	day 1

Collaborators and Investigators

• Sponsor: Centre Antoine Lacassagne

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2020
• Primary Completion (Estimated): December 31, 2099
• Study Completion (Estimated): December 31, 2099

Study Registration Dates

• First Submitted: February 14, 2025
• First Submitted That Met QC Criteria: February 24, 2025
• First Posted (Actual): February 28, 2025

Study Record Updates

• Last Update Posted (Actual): May 29, 2026
• Last Update Submitted That Met QC Criteria: May 27, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Blood Specimen Collection
• Other Study ID Numbers: 2018-61

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: pseudonymised data will only be collected
• IPD Sharing Time Frame: at the end of study
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No